ProCE Banner Activity

NADIM II: Phase II Trial of Neoadjuvant Nivolumab + Chemotherapy vs Chemotherapy in Resectable Stage IIIA/B NSCLC

Slideset Download
Conference Coverage
This trial confirms benefit of adding neoadjuvant nivolumab to chemotherapy in patients with resectable stage IIIA/B NSCLC, with a pCR rate of 36.8% vs 6.9% with neoadjuvant chemotherapy alone and no impediment to definitive surgery.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab